Slides
Page 1
Investor Presentation For Q1FY2027Delivering Care & Cure
Page 2
Safe Harbor 2 This presentation has be en prepare d by and is the sole responsibility of Gufic Biosciences Limited (the “Company”) . By accessing this presentation, you ar e agreeing to be bound by the trailing restrictions . This presentation does not constitute or form part of any offer or invitation or inducem ent to sell or issue, or any solicitation of any offe r or re commendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in conne ction with, any contract or commitment the reof . In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of a ny jurisdiction, including India . No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness , accuracy, completeness or correctness of the information or opinions contained in this presentation . Such information and opinions are in al l events not current after the date of this presentation . There is no obligation to update, modify or amend this communication or to otherwise notify the re cipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate . Certain statements contained in this presentation that are not statements of historical fact constitute “forward -looking statements .” You can generally identify forward looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expe ct”, “intend”, “may”, “obje ctive”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import . These forward -looking statements involve known and unk nown risks, unce rtainties, ass umptions and othe r factors that may cause the Company’s actual results, performance or achievements to be mate rially different from any future results, pe rformance or achievements expressed or implied by such forward -looking statements or othe r projections . Important factors that could cause actual results, performance or achievements to diffe r mate rially include, among others : (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, ( c) chang es in regulatory norms applicable to the Company, (d) te chnological changes, (e) inv estment income, (f) cash flow projections, and (g) other risks . This presentation is for general information purposes only, without regard to any specific obje ctives, financial situations or informational needs of any particular person . The Company may alte r, modify or otherwise change in any manne r the content of this presentation, without obligation to notify any person of such change or changes .
Page 3
Q1 FY27 Business & Financial Highlights
Page 4
Direction: Scale-up is deliberately paced. The site’s cost base is already in the reported numbers; the operating leverage it was built to create sits behind the certifications now in progress. Indore Facility update: The Manufacturing Platform 4 We have built one of the most advanced lyophilized injectable facilities, commenced production in October 2024 Designed for WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards, it houses: Lyophilized vials – 5 million/month Liquid vials – 6 million/month Ampoules – 10 million/month The qualification phase is behind the site. Q1 work moved to capability extension — the depot and microsphere suite is at the verge of completion, enabling manufacture of long-acting depot presentations Set-up commenced for a spray-dried route to a lipid- based antifungal, alongside qualification of a conventional route for the same format. These are formats very few Indian sites operate; both are targeted to become operational during the year. Milestone Target Status & Commentary Installation & Operational Qualification (IQ/OQ) October 2023 ✅ Completed – facility meets WHO GMP , EU GMP , ANVISA, MHRA, USFDA design standards Performance Qualification (PQ) All Lines & Utilities Dec 2023 – Jun 2024 ✅ Completed with multiple container trials; parameters locked Media Fills (Aseptic Process Simulations) Jul 2024 – Oct 2024 ✅ Completed for all four lines; sterility validated Product Permissions from State FDA Ongoing 🟡 203 approvals received to date; more in pipeline Tech Transfer for existing products from Navsari & Process Validation Batches for initial products Oct 2024 – ongoing 🟡 Completed for 40 products; stability studies in progress. 27 more products under development Vendor Audits Indian Pharma Majors H1-FY26 🟡 20+ completed, more lined up; CMO contracts commenced 30% Capacity Utilization FY26 🟡 On-track Global Regulatory Clearance EU GMP & UK MHRA FY27 🟡 EU audit completed; certification awaited US FDA FY29 🔵 Filed with US authorities on behalf of a client to trigger inspection; Gufic participates as a pure-play CDMO partner Timeline of our phased approach
Page 5
Indore Plant: The Journey So Far 5 What We Delivered Quarter by Quarter Gufic Advantage Fully Integrated Injectable Platform Quarter Milestone Detail / Evidence Q4 FY25 (Capitalized) Commercial production commenced Oct 2024 first batch; plant capitalized Q3 FY25 Q1 FY26 (Apr-Jun '25) First revenue contribution Navsari saturated; all incremental growth = Indore. High volume molecules shifted in phase 1. 145 State FDA approvals. 9 Lyo + 3 Liquid + 3 Ampoule tech transfers done; 8 in progress Q2 FY26 (Jul-Sep '25) 40 tech transfers completed; 27 under development Product mix shifted to volume products. 18 CMO vendor audits completed. Q3 FY26 (Oct-Dec '25) On track for 30% capacity utilization 203 State FDA approvals received. 20+ vendor audits. EU competent authority audit completed first week December 2025. Q4 FY26 (Jan-Mar '26) Scale up of phase 1 molecules commenced in CMO; regulatory audit focus GLP-1 validation batches (for big pharma client) executed in Jan 26. CMO client migration underway from Navsari Unit-2 to Indore Q1 FY27 (Apr-Jun '26) Capability extension and regulatory sequencing Depot and microsphere suite nearing completion; spray-dried and conventional routes for a lipid-based antifungal under set-up; contract-client migration continuing Barrier Why It Matters Lyophilisation at scale One of the largest Indian companies that can manufacture lyophilized injectables at scale. Multi-format complexity Lyophilized + Liquid Vials + Ampoules + Microspheres + NDDS (DCB, DCS) + Depot — very few companies can run this breadth under one roof Regulatory multi-accreditation (Indore + Navsari) WHO GMP + EU GMP + UK MHRA + ANVISA + TGA + Health Canada + Russian GMP + Oman GMP + Iraq GMP + UAE GMP — 10+ concurrent accreditations = moat against new entrants Batch size economics Indore batch sizes (100K+ vials/batch) vs Industry avg (40K) = 2.5x unit economics for export (QP release cost fixed per batch, not per vial) CDMO credibility 20+ Indian pharma majors have audited or are CMO partners — this is the ultimate third-party quality validation
Page 6
Direction: Formulary depth ahead of portfolio breadth, differentiated delivery formats as the point of difference, and scalerebuilt on a settled channel and a clean receivable base. I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care 6 A. Critical Care Cluster Hospital-first execution to widen ICU account coverage and compound molecule- class share through advanced critical-care injectables. B. Sparsh Scaling a hospital + nursing-home platform by tightening execution infrastructure and deepening share of the “hospital wallet” in critical categories. Theme Q1 FY27 update First-in-India launch AWABAC — a monobactam and beta-lactamase inhibitor combination for difficult-to-treat gram-negative infections — launched following expiry of the innovator patent, and introduced across corporate, tertiary and secondary care networks. Depth ahead of breadth Emphasis on widening coverage within hospital groups already served and compounding share inside molecule classes, rather than adding portfolio width. Route to formulary Round tables, continuing education and national webinars supported the launch, alongside participation in fungal-infection and critical-care scientific forums. Positioning aligned throughout to antimicrobial stewardship. Portfolio anchor Advanced gram-positive, gram-negative and antifungal classes — high- acuity, lyophilised and hospital-administered. Precisely the profile the Indore platform was built to serve. Pipeline Continued evaluation of niche hospital anti-infective and supportive-care assets, with regulatory and market-readiness work progressing for subsequent launches. Theme Q1 FY27 update The reset is behind us The division now operates entirely on the clearing-and-forwarding and stockist architecture, with the distributor data layer live. Outstanding days are inside standard trade terms and hospital onboarding has resumed at scale. Delivery systems as the moat The dual-chamber bag — a closed drug-delivery format, first in India for anti- infectives — secured acceptance across a widening set of leading tertiary and corporate institutions, and now contributes a growing share of the division. Education where it counts Clinical programmes directed at the nursing and cath-lab technician cohorts who handle the format in practice Shift towards own manufacture Promotional focus moved towards in-house manufactured brands — improving margin quality and supply reliability, and connecting the division directly to utilisation of the Company’s own capacity. Balanced coverage, pull-led Coverage now weighted evenly between nursing homes and corporate hospital chains, with the commercial approach moving from volume placement to pull-led brand and protocol building. Cardiac packaging and identity refreshed. New geographies and pipeline Entered the North-East and Jammu & Kashmir. In preparation: a chondroprotective agent; a thrombolytic and a synthetic anticoagulant for cardiac; a first-of-its-kind cyclic lipopeptide presentation in India; a premium contrast media relaunch on a DMF-grade active; and total parenteral nutrition.
Page 7
Complex injectable pipeline for the hospital platform 7 Domestic Business Breakup Others Critical Care Division Infertility Division Total Revenue Breakup International Business Domestic Business CMO Bulk Drugs & API Drug Class Unique Advantages Complexity in Manufacturing Novel β-lactam/β- lactamase Inhibitor Combo Targets multi-drug resistant Gram-negative bacteria; highly effective for severe hospital- acquired infections. Complex formulation with dual agents requires precise blending, stabilization, and maintaining consistent potency against multi-resistant bacteria. Advanced Carbapenem Combination Broad-spectrum efficacy against resistant Gram- negative pathogens, including carbapenem- resistant strains. Manufacturing challenges include stabilizing multiple compounds while preserving individual activity and minimizing cross-reactivity to ensure therapeutic efficacy. Next-Generation Echinocandin Improved dosing interval and effectiveness against Candida and Aspergillus species in systemic infections. Manufacturing complexity due to novel structure requiring stringent stability controls to prevent degradation and ensure high bioavailability. Broad-Spectrum Tetracycline Derivative Effective against both Gram-positive and Gram- negative organisms, including drug-resistant strains. Dual formulation (tablet and injectable) necessitates specialized production processes to maintain bioavailability and potency for each form. Acid-Stable Fluoroquinolone Enhanced activity in acidic environments, ideal for tissue infections such as abscesses with lower pH. Complex synthesis due to acid-stable structure; requires advanced stabilization methods for bioavailability across different formulations. Siderophore- Cephalosporin Targets resistant Gram-negative bacteria by utilizing an iron transport mechanism to penetrate bacterial cells. Manufacturing complexity involves managing the molecule’s chelating properties to maintain stability and targeted bacterial cell entry. Respiratory-Targeted Fluoroquinolone Broad effectiveness in respiratory and skin infections with enhanced activity against drug- resistant pathogens. Stabilizing fluoroquinolone structure in tablet and injectable forms demands specialized manufacturing to maintain consistent potency and patient safety.
Page 8
Direction: Depth of clinic wallet share rather than centre count in fertility; and in Zenova, a move from single-brand dependence and acute injectables to a broader, prescription-led chronic base. II. Women’s Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae 8 A. Ferticare Cluster Scaling a high-science fertility franchise by owning Reproductive Immunology and expanding the stimulation portfolio with cost-effective differentiation. B. Zenova Upgrading portfolio quality by scaling prescription-led power brands, expanding women’s health lifecycle coverage, and improving execution consistency. Theme Q1 FY27 update Category leadership held Guficin Alpha retains market leadership in recurrent implantation failure and continues to lead immunology-driven reproductive support — a category the division effectively created. Wider share of the cycle The Puregraf group secured entry into major corporate IVF chains. Unogem, the super-pure urinary FSH, is positioned against recombinant alternatives on purity and cost, with Supergraf building in the poor-responder segment. Evidence, not promotion Investigator-led observational studies with senior Indian IVF clinicians were initiated during the quarter. In this segment published evidence outlasts any campaign. Academic leadership A structured mentor-mentee programme and engagement with Indian and international reproductive medicine societies continued through the quarter. Convenience formats Pre-filled syringe presentations continue to be introduced across the portfolio, with further presentations and a probiotic combination planned later in the year. Theme Q1 FY27 update Mix shift by design Dependence on injectables continues to reduce deliberately while prescription- led and chronic therapies carry the division. The declining injectable line is a portfolio decision, not a demand signal. A new growth layer Fertiforce-M and Fertiforce-F gained prescription acceptance with a consistent month-on-month trend, establishing an infertility and reproductive-health adjacency. A broader core Power brands remain the anchor of the division, with growth increasingly broad- based across established and emerging brands rather than concentrated in one. First-mover pipeline Two differentiated introductions ahead — an in-licensed chondroprotective agent for osteoarthritis with a long clinical record in its home market, and a brand addressing the metabolic-ovarian segment built around the emerging clinical nomenclature. Scientific base Education and round-table formats continued across both gynaecology and orthopaedics.
Page 9
Direction: A deliberate build in aesthetics — a full portfolio is the precondition for clinics consolidating with one supplier;and in therapeutics, a franchise that compounds quietly on protocol-mandated demand. III. Botulinum Toxin Platform. Therapy Focus: Aesthetics & Neurology 9 A. Aesthaderm Scaling from a toxin brand into a full-stack aesthetics platform by widening injector creation, strengthening evidence, and unlocking chain-clinic scale. B. Neurocare Scaling the Therapeutic Toxin Franchise by creating new injectors in guideline- driven indications and expanding beyond neurology into adjacent specialties. Theme Q1 FY27 update Market position Number two in India in botulinum toxin type A, manufactured from the Company’s own strain with no third-party dependence for the active — a position no other Indian company holds. Closing the portfolio gap The in-licensed dermal filler and biostimulator portfolio from the Company’s Canadian partner continues through supply and regulatory steps, with launch planned during FY27. It requires no capital expenditure. Category creation is the constraint Adoption is mediated almost entirely through trusted clinicians. The task is building the category rather than capturing share within it. Injector infrastructure Cadaver laboratories and hands-on workshops continue to build a repeatable injector-training capability — the bridge to cross-category adoption once fillers enter the portfolio. Organised chains Activation of organised clinic chains remains the primary pathway to repeatable scale. Theme Q1 FY27 update Guideline-driven indications Post-stroke spasticity, cerebral palsy, dystonia, chronic migraine and urological indications — protocol-mandated settings where adoption is slow to establish and recurring once established. Coverage The largest therapeutic toxin team in India, with coverage extending into Nepal. Category expansion Extending beyond core neurology into urology, ophthalmology, pain management and neurosurgery. Institutional channels Structured training programmes and institutional and government tenders provide clinical credibility and repeat-volume visibility together. Franchise character A long-duration, low-promotion-intensity business that does not require commercial acceleration to sustain repeat volume.
Page 10
Direction: From a herbal single-brand franchise to a science-led chronic care platform — two established pillars, an allopathicadjacency opening, and a widening prescriber base. Volume-led recovery in the core. The Sallaki range regained growth momentum and outperformed its relevant product market, having declined in the comparable period a year earlier. Volume-led recovery is the sustainable kind. A second pillar scaling. VonpHa, the division’s potassium-competitive acid blocker, continues to expand unit volumes in a large and growing acid-suppression market — establishing gastrointestinal therapy as a genuine second pillar alongside pain. The overlap thesis, validated. Gufispon, the division’s newest pillar, continues to demonstrate the Ayurveda-orthopaedics crossover and is now a priority promotion brand. A deliberate step into allopathic pain. Q1 was spent preparing the NaproPure range — an NSAID and an NSAID-with-prokinetic combination — the division’s first structured entry into allopathic pain management. Market survey and launch planning were completed for rollout in Q2. Building the prescriber pipeline. The monthly scientific webinar series, continuing education at Ayurvedic colleges, round tables and patient screening initiatives continued through the quarter, extending reach to the next generation of prescribers. FY27 pipeline. Collagen and calcium combinations for joint care, continued gastrointestinal expansion, and scale-up of the division’s newest brands. IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro 10 Nutra, Ayurveda & Others Repositioning the portfolio as a science-led chronic-care platform in pain, arthritis and GI—driving sustainable reach through differentiated formulations and next-gen prescriber ecosystem building.
Page 11
Breadth by design. Approvals and renewals across eight countries this quarter, spanning Europe, MENA, Africa and South-East Asia — including a five-presentation therapy basket cleared in a single market and a manufacturing site GMP renewal. V. International Business: Shifting international growth from opportunistic filings to an IP-owned, complex- injectables-led export & licensing engine. 11 Strategy: Why We Changed the Model Gufic's international business historically was a distributor-led, opportunistic- filing model. The FY26 pivot is structural: we are moving to an IP -owned, complex-injectable-led market access model where Gufic holds the Marketing Authorisation, controls the IP , and monetises assets through three mechanisms — direct supply, out-licensing, and tech-transfer fees. Regulatory update for Q1 FY2027 Old Model New Model Distributor holds MA (loses control) Gufic holds MA through Gufic Ireland (EU direct access) Opportunistic, crowded molecules Complex injectables with fewer credible competitors Single-market filings Therapy-basket, multi-country DCP filings Volume-led, price-sensitive Licensing + supply: recurring fee + supply revenue Single Site Manufacturing Dual-site + Own MA Approval received Country / Authority Date Product A Armenia (AMPRA) Q1 FY 2027 Product B — renewal Syria (MOH) Q1 FY 2027 Product C Morocco (AMMPS) Q1 FY 2027 Product D — variation, additional API source approved South Africa (SAHPRA) Q1 FY 2027 Product E Bosnia & Herzegovina (MOH) Q1 FY 2027 Products F–J — five-presentation basket, single therapy area Chad (MOH) Q1 FY 2027 Product K Malaysia (NPRA) Q1 FY 2027 Product L Malaysia (NPRA) Q1 FY 2027 Manufacturing site — GMP renewal Uganda (NDA) Q1 FY 2027
Page 12
VI. Near Term Indore Scale Up Plan: Converting complex injectables expertise into a global sales and licensing engine. 12 Molecule Therapeutic class Regulated Market Dossier Readiness Current Market Size (US$Mn) 1 PPI with high acid suppression stability ✅ 207.4 2 PPI with broad ulcer management use ✅ 176.8 3 Glycopeptide gold standard for MRSA coverage ✅ 176 4 Long-acting glycopeptide for Gram-positive coverage ✅ 104.7 5 Next-gen glycylcycline for multi-drug resistant infections ✅ 104.2 6 Macrolide and respiratory infection role ✅ 34.4 7 Long-acting macrolide with extended tissue penetration ✅ 16.9 8 Cornerstone TB agent ✅ 3.7 Total (Select countries in EU, LATAM & ROW) 824.1 RA Status--> Key Products with Stringent Countries-Ready Dossiers Strategic Roadmap (3–5 Years) Market Share Goal: Capture 5–10% in identified geographies Portfolio Expansion: Build on current high-value molecules, adding new products from Indore Manufacturing & Capacity Alignment Current Production: EU-GMP Unit II (Navsari) Next Phase: Scale-up at Indore facility will de-bottleneck Navsari & add new products to portfolio Operational Leverage Capacity Unlock: Tech transfer to Indore + domestic CMO shift → frees Navsari for exports Export Growth: Volumes already ramping as Navsari capacity opens up Strengthening the Global Partnering Model A major global health organization has partnered with us on one of our most complex injectable assets, providing access to 109 public health markets worldwide Strong deal flow across Turkey, Brazil and India (for US market) via out-licensing and tech transfer. Gufic Ireland holds the Company’s first Marketing Authorisation in the EU, giving direct access to European markets. In Q1 FY27 approvals and renewals were secured across eight countries spanning Europe, MENA, Africa and South-East Asia, and dossier submissions progressed across West and East Africa. European GMP certification for the new site remains awaited, with corrective action responses submitted and regulator audits scheduledat both manufacturing sites.
Page 13
Gufic’s R&D Focus: Peptides & Critical API Self-Reliance Novel Drug Delivery Systems (NDDS) Clinical Programs 13
Page 14
Research & Development 14 A. Peptides & Critical API Self-Reliance Gufic is building in-house peptide API development capability — reducing dependence on Chinese API supply chains and creating a manufacturing moat for complex molecules including GnRH agonist depots, somatostatin analogues, and GnRH agonist microspheres. This is strategically aligned with India's own pharma supply-chain resilience push. B. Novel Drug Delivery Systems (NDDS) Format Advantage Stage Dual Chamber IV Bags Eliminates reconstitution error, prevents contamination — Technoflex collaboration; first-in- India for anti-infectives Commercially launched; Sparsh TAM expansion trigger Dual Chamber Syringes Streamlined reconstitution, precise dosing, sustained sterility Multiple products in development pipeline Depot Injection (Microspheres) Monthly/quarterly dosing — improves compliance, reduces nursing burden D2/D3 partial agonist LAI, D2 antagonist LAI, GnRH agonist depot, GnRH agonist microsphere, somatostatin analogue — all in pipeline Liposomal Formulation Reduced toxicity vs conventional; higher therapeutic index in antifungal therapy Lipid-complex polyene antifungal — US/EU block deal signed C. API Development — Reducing Supply Chain Dependence API Category Strategic Goal Antifungals (API) Develop in-house to reduce Chinese dependence for Amphotericin B, Caspofungin, Voriconazole Anticoagulants (LMWH, unfractionated heparin, synthetic Xa inhibitor) In-house API development for LMWH class (low-molecular- weight heparin) — high-value, complex manufacturing Tetracycline-class antibiotic (API) Tetracycline-class antibiotic API — in-house for domestic + export Progestins (API) Supports Ferticare franchise self-reliance Beta-3 Adrenergic Agonists, Antidiabetics Future chronic-care platform adjacent plays Cyclopeptide Hormones (API) Supports gonadotropin/GnRH platform
Page 15
Research & Development 15 Clinical Programs — 17 Active/Pipeline Studies Phase Count Therapy Areas Ongoing Clinical Trials 5 Reproductive immunology (Guficin Alpha/RIF), Botulinum Toxin (Aesthaderm), Gonadotropin (Puregraf), Wound healing, Phase III biosimilar (rFSH ) Pipeline Clinical Studies 12 NDDS formats, women's health adjacencies (endometriosis, PCOS), antifungal pipeline, CNS long-acting injectables, antiviral Selvax (Australia) — Long-Horizon Immuno-Oncology Optionality Gufic holds India and partial European rights to Selvax's SVX programme — a staged, animal-to-human immuno-oncology project. This is explicitly framed as a long term scientific option, not a near -term revenue lever. Total cumulative investment remains modest (BSE intimation April 29, 2026: USD 50,000 tranche for 378,350 shares at AUD 0.20; total holding now 16,85,350 shares). Programme Stage Key Data SVX-1001 (Murine model) Completed Preclinical proof-of-concept established SVX-2001 (Canine antibody) Commercialisation roadmap arm established Phase I in dogs (soft-tissue sarcomas): 68.4% clinical benefit rate, 25% complete remission, 42% stable disease SVX-3001 (Humanized anti-CD40 agonist) Advanced cell-line development; IP filed; entering international patent phase Targets 'cold' → 'hot' tumour conversion; >80% clearance in preclinical mesothelioma; 100% cure vs 0% FOLFIRINOX in pancreatic adenocarcinoma models
Page 16
Strategic Initiatives 16 Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Botulinum Toxin range of products through introduction of fast acting injectable and topical formulation (first in India and world) Commercialization of immuno -oncology therapy Leverage new biological technology platform to develop preventive and curative medical care for fatal viral infections Increase market share in contract manufacturing beyond paranterals to other drug delivery systems
Page 17
Profit & Loss Statement 17 Particulars (in Rs. Crore) Q1 FY27 Q4 FY26 Q1 FY26 FY26 FY25 Total Revenue 260.8 252.1 226.9 940.5 819.8 EBITDA 47.2 44.7 33.2 152.9 138.6 EBITDA Margin % 18.09% 17.74% 14.60% 16.26% 16.91% Profit before Tax 30.1 27.6 16.3 85.5 94.4 PBT Margins % 11.56% 10.96% 7.1% 9.09% 11.52% Tax 8.2 7.1 4.2 22.3 24.5 Profit After Tax 22.0 20.6 12.1 63.2 69.9 PAT Margin % 8.44% 8.16% 5.30% 6.72% 8.53%
Page 18
Company Overview
Page 19
About Gufic Biosciences 19 One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products BUSINESS STRUCTURE DOMESTIC BUSINESS 8 well defined Strategic Business Units Field force of ~1,000+ Product Portfolio in 15+ Therapy Areas CMO BUSINESS One of the largest facility for Lyophilization 70+ CMO Partners 50+ Products BULK DRUG BUSINESS Exclusive facility for API Specialization in • Anesthetics • Anti Fungal • Antibiotic INTERNATIONAL BUSINESS Operation spread across more than 20 countries 130+ Products registered globally 150+ products in pipeline for registration Moving in the right direction...with a well -defined business structure
Page 20
World Class Manufacturing Infrastructure 20 Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized/Powder Injectables Facility Natural Products (Topical/Liquid) API Facility Capacities Lyophilized – 18 mn vials p.a. Ampoule – 12mn p.a. Ointment – 6mn tubes p.a. Lotion – 6mn bottles p.a. Syrup – 6mn bottles p.a. PFS – 2.8mn PFS p.a. Lyophilized Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Capacities Lyophilized – 30mn vials p.a. PFS – 30mn PFS p.a. Natural Products Facility Capacities 60mn capsules p.a. 3.6mn powder p.a. WHO GMP, Philippines BFAD, Nigeria NAFDAC, Cambodia MOH, Kenya PPB, Ethiopia FMHACA, Thailand MOH, Sri Lanka NMRA EU GMP (Hungary), ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA, Uganda NDA, SAHPRA South Africa
Page 21
New Manufacturing Infrastructure 21 Unit - III at Indore Penem Block Lyophilized/Powder Injectables Facility Capacities Lyophilized Inj – 60 mn vials p.a. Liquid Inj (Ampoules) – 120mn p.a. Liquid Inj (Vials) – 72 mn units p.a. Dedicated facility for Penem Carbapenems (Lyophilized / Dry Powder Inj / Oral Solids / Dual Chamber Bags) Capacities Capability to cater to regulated markets such as US & EU UPDATE ON INDORE From Build to Benchmark Lyophilized – 3mn vials p.a. Dual Chamber Bags 2.4 mn IV bags Dry Powder Inj 30 mn Vials Indore Commercial Production Achieved
Page 22
Botulinum Toxin Facility 22 Gufic has built a state -of-the -art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and efficacy of Botulinum toxin Gufic and Prime bio, to develop several innovative formulations with Botulinum toxin in the field Dermatology, Neurology and Pain Management
Page 23
Consolidating the Domestic Branded Business 23 Doctors Reach 1,20,000+ Prescribers 30,000+ Retail Reach 1,10,000+ INFERTILITY Field Force: >150 Therapy Areas: Hormones, Recombinant Products, Infertility Supplements CRITICAL CARE Field Force: 250 Therapy Areas: Antibacterial, Antifungal, Pain Management, Blood products, GI Immuno modulator MASS SPECIALITY Field Force: >180 Therapy Areas: Anti Infectives, Gastro, Gynaecology, Respiratory, Nutraceuticals, Dermaology ORTHO – GYNAEC PRODUCTS NATURAL AND NUTRACEUTICAL PRODUCTS Field Force: >300 Therapy Areas: Bone Health, Pain Management, Immunity, Gastro, Stress, Nutraceuticals, Wound care, Respiratory, Gynaec DERMO – COSMECTICS PRODUCTS Field Force: >60 Therapy Areas: Bone Health, Pain Management, Fractures, Arthritis, Pregnancy, Post Menopausal Field Force: >40 Therapy Areas: Neurotoxin, Emollients, Antiaging , Cleansers, Pre & Post Procedure, Hyperpigmentation, Sunscreens SKU’s 200+ Products 100+ Venturing into new futuristic therapy areas : Biologicals and Immuno -Oncology Hospital Coverage 80 % of Tertiary care, Presence in Government Institutions
Page 24
Expanding Creditability in CMO Business 24 OUR ESTEEMED PARTNERS Doxycycline Tigecycline Gonadotropins Liposomal Amphotericin B Micafungin Remdesivir One of the Largest Supplier of Formulations 70+ Companies Offer CMO services for India and Global Markets Reliable CMO service for quality products over a decade 150+ Products across multiple therapy areas
Page 25
Expanding Geographical Reach 25 CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZUELA | SUDAN | ETHIOPIA | ECUADOR | PERU | PARAGUAY | NIGERIA | SOUTH AFRICA | EGYPT ZIMBABWE | UGANDA | YEMEN | SRI LANKA | MYANMAR | PHILIPPINES | THAILAND | CAMBODIA | VIETNAM | MALAYSIA | UKRAINE JORDAN | SYRIA | GEORGIA | UZBEKISTAN | KAZAKHSTAN | NEPAL | RUSSIA | AUSTRALIA 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries)
Page 26
Building API Capabilities 26 Special Facility dedicated to API Focused on developing non infringing, novel, cost effective and scalable chemical process for APIs, Peptides and Cyclopeptides The categories of API’s manufactured are antifungals, antibacterial, anesthetics and intermediates for antifungals Presence in 25 countries worldwide 70 customers PAN India
Page 27
Strong Partnership & Licensing Deals 27 Therapy Area: Toxins Strain transfer, Tech transfer, formulation development and manufacturing at Gufic Therapy Area: Infertility Tech transfer and Clinical development(Phase III) of the product at Gufic Therapy Area: Dermo Cosmetics Technical collaboration and Product Development Therapy Area: Recombinant products and Anti Infectives Collaboration on several API to develop new product Through our collaborations with global partners that are researching to expand the frontiers of pharma and biotechnology, Gufic will be a technology bridge to the future of healthcare and economical patient care in India European leader in IV drug delivery systems. Collaborated with Gufic to launch Dual Chamber Bags for the 1st time in India for anti - infectives
Page 28
Extensive Sales, Distribution IT Infrastructure in India 28 2 Central Warehouses located in North Delhi and West Bhiwandi 23 Carrying & Forwarding (C&F) agents across India 1,200+ Stockists for effective distribution across India Pan India Presence with a field force of 1,000+ Retail coverage of more than 1,10,000 retailers Doctors Reach of 1,20,000+ IT Infrastructure Integrated IT Systems with Sales and Distribution Infrastructure SAP S4 HANA (being Implemented) across all Departments Tablets, Sales Force Automation and Effectiveness tools in place
Page 29
Growth Levers 29 1 2 3 INDIA BUSINESS • Consolidation of the Critical Care Infertility business • Entry into new therapy areas Dermatology - Aesthaderm • Strategic focus on Healthcare division with entry into Ortho Gynecology products through a new division Stellar • Build a robust pipeline of new products • Build up the licensing products portfolio INTERNATIONAL BUSINESS • Expand our presence in regulated markets such as US EU • Gradually commercialize the pipeline products • Explore newer geographical locations CMO BUSINESS • Scale up the manufacturing capacity • Consolidation of the clients offer more products to existing clients • Expand the customer base • New product offerings
Page 30
Our Robust R&D and Clinical team to augment growth 30 Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Major Projects in Pipeline 50+ across all therapy areas Anti Infectives: 11 Dermatology: 7 Gynaec: 6 CNS: 4 Anti Fungal: 3 Oncology: 3 Special / NDDS Projects Innovative formulations of Botulinum Toxin Liposomal Amphotericin-B Injection Depot Injection Dual Chamber IV Bags Dual Chamber Syringes Strong Clinical team comprising of Medical Regulatory Product Development Capabilities to take Synthetic and Biological Projects across Phase II and Phase III clinical trials Projects in various Clinical Phases Ongoing: 5 Pipeline: 12 Pharmacovigilance Team
Page 31
Historical Financials
Page 32
Historical Financials 32 Particulars (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Income 943.1 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 152.9 138.6 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 16.21% 16.83% 18.48% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 85.5 94.4 115.7 106.7 126.8 57.7 30.1 40.2 PBT Margin % 9.06% 11.46% 14.31% 15.39% 16.21% 11.74% 7.83% 11.18% Tax 22.3 24.5 29.5 27 31 13.5 7.4 13.4 Profit After Tax 63.1 69.9 86.2 79.7 95.8 44.2 22.7 26.8 PAT Margin % 6.69% 8.49% 10.66% 11.50% 12.25% 8.99% 5.90% 7.45%
Page 33
Historical Balance Sheet (Equity & Liabilities) 33 EQUITY & LIABILITIES (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 654.2 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 664.2 601.3 532.5 347.8 269.1 173.4 129.3 75.4 Non-Current Liabilities Financial Liabilities i. Borrowings 105 130.5 153.9 190.7 48 35.4 19.5 11.3 ii. Other Financial Liabilities 5.6 5.4 5 5 5 5 4.7 4.7 iii. Lease Liability 14.4 19.6 11.6 16.2 0.3 2.8 6.2 0 Provisions 18 17.5 15.4 13.3 12.4 10.2 7.9 1.9 Deferred Tax Liabilities (net) 16.6 7.8 2.1 0 0.2 1.5 0 0 Total Non-Current Liabilities 159.6 180.8 188 225.2 65.9 54.9 38.3 17.9 Financial Liabilities i. Borrowings 280.1 179.9 163.1 120.7 13.3 16.3 93.1 84.7 ii. Trade Payables Total outstanding dues of micro enterprises and small enterprises 0.5 2.2 2.3 9.8 7 3.9 0 0 Total outstanding dues of other than micro enterprises & small enterprises 198.6 156.5 163.9 120.5 134 109.2 117.1 89.7 iii. Other Financial Liabilities 16 15.2 13.7 10.8 11.4 15.3 10.8 12.5 iv. Lease Liability 5.2 6.2 4.3 6.6 2.8 3.4 3.4 0 Provisions 4.5 4.4 4.7 4.2 4.9 4.6 6.6 3.4 Other current Liabilities 11 23.1 17.4 12.5 12.4 9.5 8.7 7.3 Current Tax Liabilities (net) 1.86 - 2.5 3.1 0.7 1.6 0 3.1 Total Current Liabilities 517.76 387.5 371.9 288.2 186.5 163.8 239.7 200.7 TOTAL EQUITY & LIABILITIES 1341.6 1169.6 1092.4 861.2 521.5 392.1 407.3 294
Page 34
Historical Balance Sheet (Assets) 34 ASSETS (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 467.1 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.2 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 22.1 21.8 307.1 169.6 40.9 13.4 30.6 9.6 Right of use assets 17.8 24.5 14.9 32.1 9.1 5.8 9.3 0 Financial Assets i. Investments 2.9 2.8 1.8 0.8 0 0 0 0 ii. Loans 0.5 0.2 0.4 0.3 0.2 0.3 10.3 4.2 iii. Other financial assets 11.4 9.7 8.9 8.1 9.1 11.3 0 3.8 Deferred tax assets (net) 0 0 0 1 0 0 0.6 0.7 Other non-current assets 13.3 5.3 15.05 57.7 35.3 6.5 10.1 5 Total Non Current Assets 541.3 545.8 492.05 397.1 200.7 131.5 134.2 94 Current Assets Inventories 324.5 216.9 200.5 183.5 115.6 94.4 122.5 114.2 Financial Assets i. Trade Receivables 297.4 314.6 329.9 205.5 151.6 124.5 107 96.7 ii. Cash and cash equivalent 60.3 14.9 1.1 28.6 11.6 6.2 4.3 3.9 iii. Bank balances 14 13.3 12.3 18.1 15 7 12.1 8.7 iv. Loans 0.7 0.3 0.3 0.2 0.4 0.3 0.3 0.1 Current Tax assets (Net) 1.6 1.6 0 0 0 0 0 0 Other current assets 101.8 62.2 56.2 28.3 26.7 28.2 27.2 22.5 Total Current Assets 800.3 623.8 600.3 464.2 320.9 260.6 273.4 246.1 TOTAL ASSETS 1341.6 1169.6 1092.4 861.3 521.6 392.1 407.6 340.1
Page 35
Historical Cash Flows 35 Cash Flow Statement (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 85.5 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or Financial Items 65.2 43.8 34.1 29.6 23.2 30.8 24.7 13.4 Operating profit before working capital changes 150.7 138.2 149.8 136.3 150.1 88.5 54.8 48.7 Changes in working capital -94.8 7.4 -130.2 -135.3 -10.7 10 2.5 -33.5 Cash generated from Operations 55.9 145.6 19.6 1 139.4 98.5 57.3 15.2 Direct taxes paid (net of refund) -11.9 -22.8 -27 -27.7 -33.1 -9.4 -10.1 -10 Net Cash from Operating Activities 44.1 122.8 -7.4 -26.7 106.3 89.1 47.2 5.2 Net Cash from Investing Activities -30.9 -71.8 -102.4 -190.7 -94.6 -8.5 -42.5 -13 Net Cash from Financing Activities 32.2 -37.2 82.4 234.3 -6.2 -78.6 -4.2 7.7 Net Decrease in Cash and Cash equivalents 45.4 13.8 -27.4 16.9 5.5 2 0.5 -0.1 Add: Cash & Cash equivalents at the beginning of the period 14.9 1.1 28.6 11.6 6.2 4.3 3.9 3.7 Cash & Cash equivalents at the end of the period 60.3 14.9 1.2 28.5 11.7 6.3 4.4 3.6
Page 36
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr . Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000